Home > Clinical Trials
Check All Search

Saved trials

NOT_YET_RECRUITING
NCT07340164
Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
116 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Ovarian Cancer


Ovarian Carcinoma, Recurrent


Ovarian Cancer Metastatic Recurrent


Ovarian Cancer (OvCa)
RECRUITING
NCT05408845
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers
146 Enrollment(s)
148 Study location(s)
INTERVENTIONAL (PHASE2)
Metastatic Salivary Gland Carcinoma


Recurrent Salivary Gland Carcinoma


Stage III Major Salivary Gland Cancer AJCC v8


Stage IV Major Salivary Gland Cancer AJCC v8


Unresectable Salivary Gland Carcinoma
COMPLETED
NCT04744831
Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer
122 Enrollment(s)
63 Study location(s)
INTERVENTIONAL (PHASE2)
Advanced Colorectal Cancer
NOT_YET_RECRUITING
NCT07333937
Neratinib Combined With Fulvestrant and Eribulin in the Treatment ofHR+/HER2+ Advanced Breast Cancer
35 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Brest Cancer
RECRUITING
NCT06210776
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
800 Enrollment(s)
54 Study location(s)
OBSERVATIONAL (None)
HER2-positive Breast Cancer


HER2-low Breast Cancer


Breast Cancer


Advanced Cancer
ACTIVE_NOT_RECRUITING
NCT04704934
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
490 Enrollment(s)
156 Study location(s)
INTERVENTIONAL (PHASE3)
Gastric Cancer, Adenocarcinoma


Gastroesophageal Junction Adenocarcinoma
RECRUITING
NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
73 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Myelodysplastic Syndrome


Recurrent Acute Myeloid Leukemia


Recurrent Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia
COMPLETED
NCT06961331
Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.
86 Enrollment(s)
1 Study location(s)
OBSERVATIONAL (None)
Metastatic HER2+ Advanced Breast Cancer